Pharmacotherapy of heart failure: Impact of the 2021 guideline update on guideline-directed medical therapy assessed using a Japanese employee health insurance claims database
Int. Journal of Clinical Pharmacology and Therapeutics · 01.11.2026 · 64 (11) · 591-599
DOI: 10.5414/cp205008 ↗Kurz gefasst
Leitlinie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 01.11.2026. Verfasst von Takaya Uno und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Guideline Adherence, Heart Failure, Practice Guidelines as Topic.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Uno, T., Hosomi, K., & Yokoyama, S. (2026). Pharmacotherapy of heart failure: Impact of the 2021 guideline update on guideline-directed medical therapy assessed using a Japanese employee health insurance claims database. Int. Journal of Clinical Pharmacology and Therapeutics, 64(11), 591-599. https://doi.org/10.5414/cp205008
Vancouver
Uno T, Hosomi K, Yokoyama S. Pharmacotherapy of heart failure: Impact of the 2021 guideline update on guideline-directed medical therapy assessed using a Japanese employee health insurance claims database. Int. Journal of Clinical Pharmacology and Therapeutics. 2026;64(11):591-599. doi:10.5414/cp205008
BibTeX
@article{Uno2026,
author = {Uno, Takaya and Hosomi, Kouichi and Yokoyama, Satoshi},
title = {Pharmacotherapy of heart failure: Impact of the 2021 guideline update on guideline-directed medical therapy assessed using a Japanese employee health insurance claims database},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2026},
volume = {64},
number = {11},
pages = {591--599},
doi = {10.5414/cp205008}
}
EUVIMED